Mohammad Hirmand is VP at Turning Point Therapeutics, Inc. (TPTX). They have made 5 open-market trades across 2 companies since 2015, most recently 2022-08-17.
CIK 0001654482
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TPTX | SELL | 2022-02-09 | 2022-02-11 | $36.30 | $24K | -8.3% | -28.0% | -14.6% |
| TPTX | SELL | 2021-01-04 | 2021-01-05 | $120.42 | $2.3M | +9.4% | +9.0% | -25.2% |
| MDVN | SELL | 2016-03-04 | 2016-03-07 | $41.10 | $125K | -12.4% | +16.5% | +47.5% |
| MDVN | SELL | 2015-12-03 | 2015-12-04 | $43.40 | $47K | -21.1% | +1.2% | -18.1% |
| MDVN | SELL | 2015-11-09 | 2015-11-12 | $41.91 | $10K | -21.1% | +1.2% | -36.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.